Affymax Reports Phase 2 Clinical Dose Ranging Results of
Once-Per-Month Hematide for the Treatment of Anemia
PALO ALTO, Calif.--(BUSINESS WIRE)--Jun 25, 2007 - Affymax, Inc.(Nasdaq:AFFY) today announced that additional Phase 2 clinicaltrial results for
Hematide(TM) were presented at the European RenalAssociation-EDTA Congress being held in Barcelona, Spain by Iain C.Macdougall, M.D., a
Hematide investigator from Kings College,London. Dr. Macdougall's poster included data in previously-treateddialy...
Affymax Announces Phase 2 Clinical Trial Results of Once-Per-Month
Hematide for the Treatment of Anemia in Patients with Early- and
End-Stage Chronic Kidney Disease
PALO ALTO, Calif.--(BUSINESS WIRE)--Apr 23, 2007 - Affymax, Inc.(Nasdaq:AFFY) today announced results to date from two separatePhase 2 clinical trials of
Hematide(TM) in dialysis andnon-dialysis chronic kidney disease (CKD) patients. The data showedthat in treatment naive, non-dialysis patients
Hematide couldcorrect anemia when administered monthly at an appropriate dose.Similarly, the data...
Affymax Announces Results From Phase 2 Clinical Trial of Hematide
for the Treatment of Anemia in Dialysis Patients
PALO ALTO, Calif.--(BUSINESS WIRE)--Apr 12, 2007 - Affymax, Inc.(Nasdaq:AFFY) today announced that results available from its Phase2 clinical trial of
Hematide(TM) dosed monthly in dialysis patientswere presented this week at the National Kidney Foundation (NKF)2007 Spring Clinical Meeting. The results from thismaintenance-switch trial in patients previously treated withthree-times weekly E...